StockData
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. (COCP) stock

COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$0.98−0.03 (-3.28%)

Close on Nov 18, 2026Market cap $18.82MP/E –Yield –

Cocrystal Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cocrystal Pharma's operating income for the twelve months ending Jun 30, 2026 was -$10.11M. For fiscal 2025 it was -$9.02M. The highest annual figure on record is -$32.05K in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.02M–
FY2024Dec 31, 2024-$17.88M–
FY2023Dec 31, 2023-$18.56M–
FY2022Dec 31, 2022-$38.83M–
FY2021Dec 31, 2021-$14.22M–
FY2020Dec 31, 2020-$9.59M–
FY2019Dec 31, 2019-$48.41M–
FY2018Dec 31, 2018-$62.92M–
FY2017Dec 31, 2017-$8.26M–
FY2016Dec 31, 2016-$105.82M–
FY2015Dec 31, 2015-$53.95M–
FY2014Dec 31, 2014-$5.80M–
FY2013Dec 31, 2013-$4.08M–
FY2012Dec 31, 2012-$2.55M–
FY2011Dec 31, 2011-$3.89M–
FY2010Dec 31, 2010-$32.05K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.18M–
Q1 FY2026Mar 31, 2026-$2.36M–
Q4 FY2025Dec 31, 2025-$2.48M–
Q3 FY2025Sep 30, 2025-$2.09M–
Q2 FY2025Jun 30, 2025-$2.11M–
Q1 FY2025Mar 31, 2025-$2.34M–
Q4 FY2024Dec 31, 2024-$3.23M–
Q3 FY2024Sep 30, 2024-$5.04M–
Q2 FY2024Jun 30, 2024-$5.45M–
Q1 FY2024Mar 31, 2024-$4.16M–
Q4 FY2023Dec 31, 2023-$4.67M–
Q3 FY2023Sep 30, 2023-$4.44M–
Q2 FY2023Jun 30, 2023-$4.34M–
Q1 FY2023Mar 31, 2023-$5.11M–
Q4 FY2022Dec 31, 2022-$4.50M–
Q3 FY2022Sep 30, 2022-$5.69M–
Q2 FY2022Jun 30, 2022-$24.43M–
Q1 FY2022Mar 31, 2022-$4.21M–
Q4 FY2021Dec 31, 2021-$3.70M–
Q3 FY2021Sep 30, 2021-$3.95M–
Q2 FY2021Jun 30, 2021-$3.83M–
Q1 FY2021Mar 31, 2021-$2.74M–
Q4 FY2020Dec 31, 2020-$1.47M–
Q3 FY2020Sep 30, 2020-$2.71M–
Q2 FY2020Jun 30, 2020-$3.45M–
Q1 FY2020Mar 31, 2020-$1.96M-168.2%
Q4 FY2019Dec 31, 2019-$47.93M–
Q3 FY2019Sep 30, 2019-$1.81M–
Q2 FY2019Jun 30, 2019-$1.55M–
Q1 FY2019Mar 31, 2019$2.88M–
Q4 FY2018Dec 31, 2018-$56.30M–
Q3 FY2018Sep 30, 2018-$2.42M–
Q2 FY2018Jun 30, 2018-$2.13M–
Q1 FY2018Mar 31, 2018-$2.07M–
Q4 FY2017Dec 31, 2017-$1.83M–
Q3 FY2017Sep 30, 2017-$2.11M–
Q2 FY2017Jun 30, 2017-$2.11M–
Q1 FY2017Mar 31, 2017-$3.12M–
Q4 FY2016Dec 31, 2016-$94.39M–
Q3 FY2016Sep 30, 2016-$1.89M–

More Cocrystal Pharma figures

See a number that looks wrong?